LONA · LeonaBio, Inc.
What's happening
- LONA is up 5.16% today, trading at $5.30. — Live quote
- Volume today (3,664) is well below its 3-month average of 145,430. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.80 actual vs. $-1.29 estimated (+38.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $215.5M | $194.5M | $16.3M | $11.9M | $11.0M |
| P/E | -3.29 | -3.49 | -0.32 | -0.17 | -0.12 |
| Price/Book | 6.41 | 3.95 | 0.61 | 0.37 | 0.29 |
| ROE | -195.06% | -112.91% | -192.12% | -224.19% | -243.99% |
| ROA | -115.18% | -77.76% | -171.35% | -201.74% | -209.32% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +43.6%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-09-22; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LONA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$19.5M | -$17.2M | -$6.9M | -$7.3M | -$9.5M | -$29.6M | -$28.0M | -$27.7M |
| Net income | -$19.0M | -$32.9M | -$6.6M | -$7.0M | -$9.1M | -$28.7M | -$26.9M | -$26.3M |
| EPS (diluted) | $-0.80 | $-1.73 | $-1.68 | $-1.78 | $-2.34 | $-7.46 | $-0.70 | $-0.69 |
| EPS (basic) | $-0.80 | $-1.73 | $-1.68 | $-1.78 | $-2.34 | $-7.46 | $-0.70 | $-0.69 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $56.9M | $71.6M | $92.2M | $30.0M | $35.5M | $43.5M | $58.8M | $86.2M |
| Total liabilities | $23.3M | $22.3M | $64.4M | $3.2M | $3.6M | $6.2M | $13.9M | $28.7M |
| Stockholders' equity | $33.6M | $49.3M | $27.8M | $26.8M | $32.0M | $37.3M | $44.8M | $57.6M |
| Total current assets | $54.8M | $69.2M | $89.5M | $27.0M | $32.2M | $39.9M | $54.8M | $82.0M |
| Total current liabilities | $7.8M | $6.7M | $47.5M | $2.8M | $3.0M | $5.5M | $13.1M | $27.8M |
| Cash & equivalents | $32.3M | $32.8M | $69.3M | $20.9M | $19.9M | $26.4M | $48.4M | $68.9M |
| Marketable securities (current) | $18.7M | $34.8M | $19.1M | $4.4M | $9.9M | $10.2M | $2.8M | — |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $1.0M | $1.2M | $1.5M | $1.7M | $2.0M | $2.2M | $2.4M | $2.7M |
| Other non-current assets | $55.0K | $55.0K | $55.0K | $55.0K | $62.0K | $85.0K | $55.0K | $55.0K |
| Accounts payable | $2.4M | $1.8M | $4.6M | $266.0K | $171.0K | $867.0K | $319.0K | $388.0K |
| Accrued liabilities | $4.9M | $4.4M | $5.0M | $2.1M | $2.4M | $4.2M | $12.4M | $17.0M |
| Other non-current liabilities | $1.0M | $1.2M | $1.4M | — | — | — | — | — |
| Common stock & paid-in capital | $1.0K | $1.0K | $1.0K | $4.0K | $4.0K | $4.0K | $0 | $4.0K |
| Retained earnings | -$563.7M | -$544.7M | -$511.8M | -$428.9M | -$422.3M | -$415.3M | -$406.1M | -$391.1M |
| Accumulated other comprehensive income (loss) | -$9.0K | -$13.0K | -$4.0K | -$2.0K | -$3.0K | -$4.0K | $1.0K | $3.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.0M | -$20.9M | -$19.4M | -$4.7M | -$7.0M | -$14.7M | -$26.0M | -$23.0M |
| Investing cash flow | $16.3M | -$15.5M | -$14.6M | $5.7M | $441.0K | -$7.4M | -$2.8M | $18.0M |
| Financing cash flow | $114.0K | — | $82.4M | $0 | $24.0K | — | $34.0K | $12.0K |
| Free cash flow | — | — | — | — | — | — | -$26.0M | -$23.0M |
| Capital expenditures | — | — | — | — | — | — | $0 | $0 |
| Share-based compensation | $3.2M | $662.0K | $1.5M | $1.4M | $1.6M | $1.6M | $2.2M | $2.9M |
| Purchases of investments | $10.2M | $20.6M | $18.0M | $3.3M | $6.1M | $10.2M | $2.8M | $0 |
| Sales/maturities of investments | $26.6M | $5.1M | $3.4M | $9.0M | $6.5M | $2.9M | $0 | $18.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$102.3M | -$100.9M | -$125.5M | -$104.0M | -$64.0M |
| Net income | -$105.6M | -$96.9M | -$117.7M | -$95.6M | -$54.9M |
| EPS (diluted) | $-24.70 | $-25.19 | $-3.09 | $-2.53 | $-1.49 |
| EPS (basic) | $-24.70 | $-25.19 | $-3.09 | $-2.53 | $-1.49 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $92.2M | $58.8M | $160.2M | $258.2M | $332.0M |
| Total liabilities | $64.4M | $13.9M | $30.1M | $23.0M | $10.9M |
| Stockholders' equity | $27.8M | $44.8M | $130.2M | $235.1M | $321.1M |
| Total current assets | $89.5M | $54.8M | $154.7M | $207.5M | $260.8M |
| Total current liabilities | $47.5M | $13.1M | $28.8M | $21.4M | $9.3M |
| Cash & equivalents | $69.3M | $48.4M | $90.6M | $96.0M | $110.5M |
| Marketable securities (current) | $19.1M | $2.8M | $56.8M | $104.4M | $143.2M |
| Marketable securities (non-current) | — | — | — | $44.8M | $65.9M |
| Property, plant & equipment | $1.5M | $2.4M | $3.4M | $4.1M | $3.8M |
| Other non-current assets | $55.0K | $55.0K | $448.0K | $55.0K | $56.0K |
| Accounts payable | $4.6M | $319.0K | $129.0K | $2.5M | $567.0K |
| Accrued liabilities | $5.0M | $12.4M | $18.3M | $8.6M | $8.4M |
| Other non-current liabilities | $1.4M | — | — | — | — |
| Common stock & paid-in capital | $1.0K | $0 | $4.0K | $4.0K | $4.0K |
| Retained earnings | -$511.8M | -$406.1M | -$309.2M | -$191.5M | -$95.9M |
| Accumulated other comprehensive income (loss) | -$4.0K | $1.0K | -$349.0K | -$2.0M | -$388.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$45.7M | -$97.2M | -$100.8M | -$72.5M | -$43.1M |
| Investing cash flow | -$15.9M | $54.8M | $95.1M | $57.7M | -$4.1M |
| Financing cash flow | $82.5M | $194.0K | $493.0K | $654.0K | $97.1M |
| Free cash flow | — | -$97.2M | -$101.1M | -$73.6M | -$44.7M |
| Capital expenditures | — | $33.0K | $304.0K | $1.1M | $1.6M |
| Share-based compensation | $6.1M | $11.0M | $10.6M | $10.6M | $4.6M |
| Purchases of investments | $37.6M | $14.1M | $27.7M | $95.3M | $299.2M |
| Sales/maturities of investments | $21.7M | $69.0M | $123.1M | $154.1M | $278.6M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LONA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:02 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-22 | 8-K | 2026-09-18 | View on SEC.gov → |
| 2026-08-26 | 8-K | 2026-08-26 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-07-10 | 4 | 2026-04-09 | View on SEC.gov → |
| 2026-07-09 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-24 | 4 | 2026-06-23 | View on SEC.gov → |
Recent news
Headlines about LONA (LeonaBio, Inc.). Links open the publisher — we don’t host full articles.
-
Price-Driven Insight from (LONA) for Rule-Based Strategy
Stock Traders Daily · 2026-10-19 -
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
Yahoo Finance · 2026-09-03 -
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances
Yahoo Finance · 2026-08-17 -
Athira Pharma GAAP EPS of -$0.80 misses by $0.27
Seeking Alpha · 2026-08-17 -
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance · 2026-08-14 -
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
Yahoo Finance · 2026-08-12 -
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
Yahoo Finance · 2026-06-04 -
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
Yahoo Finance · 2026-05-27
No headlines in this category right now — try “All”.